Article Text

Download PDFPDF
Limits of 18F-Fluorodeoxyglucose Positron Emission Tomography in Recurrence Diagnosis of Borderline Ovarian Tumor
  1. Margherita Giorgini, MD*,
  2. Claudia Marchetti, MD*,
  3. Violante Di Donato, MD*,
  4. Jacopo Tesei, MD,
  5. Natalina Manci, MD* and
  6. Pierluigi Benedetti Panici, MD*
  1. * Department of Obstetrics and Gynecology, and
  2. Radiological Sciences, University of Rome "Sapienza," Rome, Italy.
  1. Address correspondence and reprint requests to Natalina Manci, MD, Department of Gynecology, Obstetrics and Perinatology, University of Rome "Sapienza," Via del Policlinico, 155-00161 Rome, Italy. E-mail: natalina.manci{at}


Most borderline ovarian tumors (BOT) occur in young women and exhibit a low malignant behavior. Nevertheless, an accurate long-term follow-up is required because, frequently, recurrence arises after many years from primary treatment, especially in patients affected by BOT with invasive peritoneal implants, which have a worse prognosis. We report the case of a pelvic recurrence of serous BOT firstly suspected by physical examination but misdiagnosed by 18F-fluorodeoxyglucose positron emission tomography and computed tomography and identified only by magnetic resonance imaging, 7 years after primary treatment. We also reviewed the literature concerning the role of 18F-fluorodeoxyglucose positron emission tomography in the management and follow-up of BOT.

  • Borderline ovarian tumors
  • Total-body FDG-PET/CT
  • Recurrence

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.